The European Commission has approved Erbitux (cetuximab) in combination with [...]
FORE Biotherapeutics has completed target enrolment in the primary central [...]
The European Commission has approved Erbitux (cetuximab) in combination with [...]
FORE Biotherapeutics has completed target enrolment in the primary central [...]